Latest news with #Semaglutide
Irish Independent
13 hours ago
- Health
- Irish Independent
Weight loss of 15pc recorded in new obesity drug trials, involving UCD professor
The findings that a new drug called CarigSema far outperforms Ozempic and other weight loss drugs - was announced in Chicago at the 85th Scientific Sessions of the American Diabetes Association. 'The REDEFINE 2 study showed that CagriSema, a new treatment in development for the disease of obesity, can allow patients with type 2 diabetes lose 15pc body weight, while putting their blood sugar levels back in the normal range,' said Professor Carel LeRoux, a leading weight-loss researcher at the UCD Conway Institute, and a principal investigator on the study. 'What patients often tell us is that they again can do all the things they want because they feel so much more functional,' said Prof Le Roux. 'We also see that the side effects are manageable and clinicians are getting much better at reducing common side effects. 'Taken together, this will allow clinicians to control the disease of obesity, which will allow us to disrupt the disease of type 2 diabetes.' CarigSema is a combination of Cagrilintide and Semaglutide. The latter is marketed under the brands of Ozempic, Wegovy and Rybelsus. CarigSema is seen as a potential follow-on treatment for people already being treated for obesity, and type 2 diabetes, or both, with Ozempic and Wegovy or Mounjaro – a drug that slows down the rate at which food leaves the stomach. CarigSema is a combination of Semaglutide, a so-called GLP-1 analogue that is better known as Ozempic, and Cagrilintide is an analogue of Amylin. An analogue in chemistry is the name for something that is similar, but not identical to something else, and often mimics its action inside the body. The GLP-1 analogues, which include Ozempic and Wegovy, act by imitating incretin, a natural hormone that decreases blood sugars and reduces appetite. ADVERTISEMENT Meanwhile, Cagrilintide, is an analogue of Amylin, another natural hormone in the body and one which promotes satiety - the feeling of being full after eating. 'In a phase three clinical trial, participants with type 2 diabetes and obesity experienced unprecedented weight loss,' said Prof Le Roux, who said that the CarigSema trial 'marks a turning point' in weight and diabetes management. 'Many participants expressed joy in regaining abilities that their condition had previously hindered – playing with grandchildren, tying shoelaces and performing daily activities became accessible once more.' The treatment, said Prof Le Roux, involves a weekly injection, which enables patients to manage their disease, and also accommodate healthier lifestyles. The REDEFINE trial results offer a 'beacon of hope' for people living with type 2 diabetes and obesity, he said, with results that promise to promote not just weight loss, but to enhance people's quality of life and well-being. 'Patients can look forward to a future where managing diabetes can lead to healthier lifestyles and renewed vitality,' said Prof Le Roux.
&w=3840&q=100)
Business Standard
3 days ago
- Health
- Business Standard
India's response to obesity drug Mounjaro 'positive', says Eli Lilly
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The US-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about ₹23.94 crore ($2.76 million) as of May, with the drug logging a 60 per cent rise in overall sales between April and May, according to data from research firm PharmaTrac. With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the US. "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24 per cent of women and nearly 23 per cent of men aged 15 to 49 were overweight or obese, up from 20.6 per cent and 19 per cent, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Time of India
3 days ago
- Health
- Time of India
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May, according to data from research firm PharmaTrac. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like An engineer reveals: 1 simple trick to get all TV channels Techno Mag Learn More Undo With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the U.S. Live Events "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24% of women and nearly 23% of men aged 15 to 49 were overweight or obese, up from 20.6% and 19%, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India.
Indian Express
5 days ago
- Health
- Indian Express
Mounjaro, Wegovy result in lower weight loss in the real world than clinical trials, says study: What explains this gap?
At a time when makers of weight loss drug Mounjaro are claiming that you can lose up to 22.5 per cent of your starting body weight over 72 weeks on its highest dose of 15 mg, a new study says the reality is quite the opposite. Researchers found that people on weight loss injectables shed fewer pounds in the real world than in clinical trials. In other words, this study indicates these drugs may not produce drastic weight loss in everyday settings. Researchers analysed data from 51,085 patients with a body mass index of 35 or greater and who were eligible for weight loss surgery and weight loss jabs. The team compared the three-year weight loss journey in 38,545 people prescribed semaglutide (sold under brand name Wegovy) and tirzepatide (Mounjaro) with 12,540 patients who underwent weight loss surgery. They found that those who underwent bariatric surgery had a significantly higher weight loss after two years, at 26.5%, compared with 5.7% for those prescribed semaglutide and tirzepatide. Semaglutide is a GLP1 receptor agonist (RA) which mimics the GLP 1 hormone and helps control blood sugar, reduce appetite and accelerate weight loss. Tirzepatide (Mounjaro) is a GLP1-RA cum GIP agonist. GIP has a role in food metabolism. The study will be presented at the American Society for Metabolic and Bariatric Surgery 2025 annual scientific meeting. 'The average patient on [GLP-1 RAs] in the real world is not getting the weight loss that we see in clinical trials,' says senior author Dr Karan Chhabra, Assistant Professor of Surgery & Population Health at Grossman School of Medicine, New York University. Does that mean that bariatric surgery will continue to be relevant? Listen in. 1) What could have been the reason for this discrepancy between weight loss in clinical trials and during real-time use of the drug? Though you have not done a data analysis on causes, what do you think went wrong? I think many patients either discontinued treatment or were not titrated (a method of assessing the concentration of a substance) up to the high doses needed for maximal weight loss. 2) Does this mean that we still need widespread studies on GLP 1 RAs? We need more real-world studies of GLP1 agonists – this study shows us that the clinical trial results do not always apply to real-world patients. Our team will be looking at this topic next – what can prescribers do to maximize the effectiveness of GLP1 RAs. 3) So far makers of weight loss drugs had claimed that their drugs were almost equivalent to bariatric surgery. How does this study challenge that perception? This study shows that in real world conditions, these drugs lead to far lesser weight loss than bariatric surgery for the average patient. 4) Who needs bariatric surgery? Rather, which set of people are more likely to benefit from bariatric surgery? Ultimately the treatment strategy should be tailored to individual patients' characteristics and preferences. Patients who do not want to be on lifelong medications, or who need 20 per cent weight loss to achieve their health goals, or who do not have insurance coverage for GLP1 RAs would be better served with surgery. 5) Do you see weight loss drugs having long-term efficacy? Weight loss drugs are effective for maintaining weight loss only for as long as they are taken. Many studies show that patients regain as much as 70 per cent of the weight lost when they stop taking these drugs. 6) Are weight loss drugs more hype than effect? No, this study underscores that these drugs are not a silver bullet but they can be highly effective when prescribed carefully by an expert physician. The goal is to get as many people to the right treatment (for obesity) as possible.
Yahoo
7 days ago
- Health
- Yahoo
Peptide and Anti-Aging Specialist Dr. Daniel Benhuri Now Offering Advanced Peptide Therapy, Including Semaglutide, in Beverly Hills and Los Angeles
Dr. Daniel Benhuri, a board-certified concierge physician in Beverly Hills, has introduced personalized peptide therapy to help patients optimize energy, metabolism, immunity, and recovery. The new service is available in-office or via concierge care throughout Beverly Hills and Los Angeles. BEVERLY HILLS, Calif. , June 16, 2025 /PRNewswire/ -- Dr. Daniel Benhuri, a board-certified internal medicine physician and highly rated concierge doctor in Beverly Hills, is now offering a full range of advanced peptide therapies designed to support weight loss, healing, hormone balance, sexual wellness, and cellular rejuvenation. Serving patients throughout Beverly Hills and the greater Los Angeles area, Dr. Benhuri's peptide programs now include widely requested options like Semaglutide, Tirzepatide, Tesamorelin, PT-141, BPC-157, and NAD+. Peptides are short chains of amino acids that function as biological messengers, helping regulate metabolism, inflammation, recovery, and tissue repair. Dr. Benhuri's therapy protocols are fully customized based on labs, medical history, and patient goals—and are now available through in-office visits or concierge care across Los Angeles. "Peptide therapy is a powerful tool that allows us to treat the root causes of fatigue, weight gain, inflammation, and low libido," said Dr. Benhuri. "These are evidence-based, well-tolerated therapies that fit perfectly into our concierge wellness model. Our patients want to optimize their lives, and peptides help us deliver exactly that." Highlights of Dr. Benhuri's peptide therapy offerings include: Semaglutide and Tirzepatide (GLP-1 agonists): Support sustainable weight loss by regulating appetite and improving insulin sensitivity. Tesamorelin: Helps reduce visceral fat and promote lean muscle development. PT-141: Enhances sexual desire and performance in both men and women. BPC-157: Accelerates healing of soft tissue injuries and provides anti-inflammatory benefits. NAD+ Therapy: Though not a peptide, NAD+ is a key coenzyme used for energy metabolism, anti-aging, and cognitive enhancement. Dr. Benhuri's comprehensive programs begin with a detailed consultation and lab review. Based on individual needs, patients receive a personalized treatment plan that may include injectable peptides, nasal sprays, or topical solutions—all sourced from high-quality U.S. compounding pharmacies. Patients also benefit from ongoing clinical monitoring and adjustments as part of his concierge approach. Known for his expertise in preventive care, weight management, and regenerative medicine, Dr. Benhuri offers these new services as a natural extension of his commitment to helping patients feel better, function better, and age with confidence. More About Dr. Daniel Benhuri Dr. Daniel Benhuri is a highly respected internal medicine and primary care physician serving patients in Beverly Hills and the surrounding areas. He offers a vast array of services, including advanced diagnostic imaging, executive physicals, medical weight loss plans, preventive care, and aesthetic treatments. By integrating concierge care and cutting-edge technology, Dr. Benhuri delivers an unmatched level of patient-focused care. His practice is located at 9400 Brighton Way, Suite 210, Beverly Hills, CA 90210. For more information or to schedule an appointment, visit or call (310) 362-1255. Media ContactDr. Daniel Benhuri(310) View original content to download multimedia: SOURCE Daniel Benhuri M.D.
